Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Surface Oncology, Inc.

https://www.surfaceoncology.com

Latest From Surface Oncology, Inc.

Deal Watch: Coherus Terminates Immuno-Oncology Alliance With Junshi

Plus deals involving Menarini/VenatoRx, Orion/Glykos, Roche/MOMA, Janssen/Elektrofi, Galapagos/BridGene along with 13 other transactions.

Deal Watch Business Strategies

Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships

Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.

Cancer ImmunoOncology

Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology

Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.

Deals M & A

Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology

Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.

M & A ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register